MYC-Amplified Prostate Cancers Show Fewer Immune Cells, Hinting at Immunotherapy Resistance
Analysis of multiple prostate cancer genomics datasets found that MYC-amplified metastatic tumors yield significantly fewer adaptive immune receptor recombination reads, suggesting reduced immune infiltration that may predict poor response to immunotherapy. Published in Oncoscience.